Effect of lipid-modifying drug therapy on survival after abdominal aortic aneurysm repair Gaurav M. Parmar, MD, MPH, Bruce Lowman, MD, Bart R. Combs, MD, Steve M. Taylor, MD, Mark A. Patterson, MD, Marc A. Passman, MD, William D. Jordan, MD, FACS Journal of Vascular Surgery Volume 58, Issue 2, Pages 355-363 (August 2013) DOI: 10.1016/j.jvs.2013.01.036 Copyright © 2013 Society for Vascular Surgery Terms and Conditions
Fig 1 Identification of eligible study participants. Journal of Vascular Surgery 2013 58, 355-363DOI: (10.1016/j.jvs.2013.01.036) Copyright © 2013 Society for Vascular Surgery Terms and Conditions
Fig 2 a, Survival from aneurysm-related mortality (n = 82). b, Survival from cardiovascular mortality (n = 131). c, Survival from all-cause mortality (n = 656). LMDT, Lipid-modifying drug therapy; SE, standard error. Journal of Vascular Surgery 2013 58, 355-363DOI: (10.1016/j.jvs.2013.01.036) Copyright © 2013 Society for Vascular Surgery Terms and Conditions
Fig 3 Multivariable adjusted hazard ratios with 95% confidence intervals (CIs) from Cox proportional hazard regression. EVAR, Endovascular repair; LMDT, lipid-modifying drug therapy; OADD, other atherosclerotic diseases or diabetes. Journal of Vascular Surgery 2013 58, 355-363DOI: (10.1016/j.jvs.2013.01.036) Copyright © 2013 Society for Vascular Surgery Terms and Conditions